[
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals (NasdaqGS:VRTX) Highlights Clinical Benefits Of ALYFTREK At Cystic Fibrosis Conference",
    "summary": "Vertex Pharmaceuticals (NasdaqGS:VRTX) presented promising clinical data on their CFTR modulator ALYFTREK at the European Cystic Fibrosis Conference, showcasing improved outcomes for patients with reduced sweat chloride levels. These developments, highlighting both positive patient outcomes and important safety considerations, likely added weight to the company's 3.6% price increase over the past month. During the same period, the broader market experienced a rise of 1.8%, suggesting that...",
    "url": "https://finnhub.io/api/news?id=d59d36f780e65045cfe0e6db15958ba94a01776e37f763a263608facf2e610d6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749316500,
      "headline": "Vertex Pharmaceuticals (NasdaqGS:VRTX) Highlights Clinical Benefits Of ALYFTREK At Cystic Fibrosis Conference",
      "id": 135110953,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex Pharmaceuticals (NasdaqGS:VRTX) presented promising clinical data on their CFTR modulator ALYFTREK at the European Cystic Fibrosis Conference, showcasing improved outcomes for patients with reduced sweat chloride levels. These developments, highlighting both positive patient outcomes and important safety considerations, likely added weight to the company's 3.6% price increase over the past month. During the same period, the broader market experienced a rise of 1.8%, suggesting that...",
      "url": "https://finnhub.io/api/news?id=d59d36f780e65045cfe0e6db15958ba94a01776e37f763a263608facf2e610d6"
    }
  }
]